← All trials
NCT02582697
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2014
- Primary completion
- Feb 1, 2022
- Completion date
- Jul 1, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of SydneyLead sponsor
- Chris O'Brien LifehouseStudy chair
- Australian and New Zealand Urogenital and Prostate Cancer Trials GroupCollaborator
- Cancer Trials IrelandCollaborator
- University of Southern CaliforniaCollaborator
- National Cancer Institute (NCI)Collaborator
- Harvard UniversityCollaborator
- University of CambridgeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.